Skip Navigation
  Search Menu
Find an Expert

 

Evan Jacob Lipson, M.D.

Photo of Dr. Evan Jacob Lipson, M.D.

Associate Professor of Oncology

Specializes in: Adults (18+ years)

Male

Expertise: Clinical Trials, Immunotherapy, Medical Oncology, Melanoma

Research Interests: Melanoma; Immunotherapy

Request an Appointment

I live in Maryland

410-955-8964
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8893
Fax: 410-955-8587

Sibley Memorial Hospital
Appointment Phone: 202-660-6500

5255 Loughboro Road, NW
1st Floor
Washington, DC 20016 map
Fax: 202-660-6501

Background

Evan J. Lipson, M.D., is a medical oncologist at the Johns Hopkins Kimmel Cancer Center as well as an associate professor of oncology at the Johns Hopkins University School of Medicine. He sees patients in Baltimore and at Sibley Memorial Hospital in Washington, DC.

Dr. Lipson earned his undergraduate degree from the University of Maryland and his medical degree from the Mount Sinai School of Medicine. He completed a residency in internal medicine at the Johns Hopkins University School of Medicine, as well as a fellowship at Hopkins in medical oncology. 

Dr. Lipson's clinical expertise is in the treatment of patients with advanced skin cancers, including melanoma, Merkel cell carcinoma, basal cell carcinoma, and skin squamous cell carcinoma, among others.

As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, Dr. Lipson focuses on evaluating novel therapies for patients with high-risk or advanced skin cancer.  He is a principal or co-investigator on multiple trials, involving partners from both industry and academia, which focus on the clinical development of antibodies that block the PD-1/PD-L1 pathway. He is collaborating to develop new methods to predict and monitor their therapeutic effects, including nuclear imaging and serum-based molecular markers. Dr. Lipson’s publications include the first description of successful PD-1 re-induction therapy (Clin Can Res 2013), and the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer (JCO 2014, NEJM 2016). 

Dr. Lipson is also an internationally-recognized educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. 

...read more

Titles

  • Associate Professor of Oncology

Departments / Divisions

  • Medicine at Sibley Memorial Hospital
  • Oncology - Medical Oncology

Education

Degrees

  • MD, Mount Sinai School of Medicine (2005)

Residencies

  • Johns Hopkins University School of Medicine / Medicine (2008)

Fellowships

  • Johns Hopkins University School of Medicine / Oncology (2011)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2008)
  • American Board of Internal Medicine / Medical Oncology (2010)

Research & Publications

Clinical Trials

View Dr. Lipson's current research trials at Sibley Memorial Hospital here.

Selected Publications

View all on Pubmed

Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19:462-468.

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016.

Lipson EJ, Bagnasco SM, Moore J,Jr, Jang S, Patel MJ, Zachary AA, Pardoll DM, Taube JM, Drake CG. Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. N Engl J Med. 2016;374:896-898.

Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32:e69-71.

Rowe SP, Luber B, Makell M, Brothers P, Santmyer J, Schollenberger MD, Quinn H, Edelstein DL, Jones FS, Bleich KB, Sharfman WH, Lipson EJ. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol. 2018 Aug 16.

Activities & Honors

Memberships

  • Seize The Days

    Founder

  • Johns Hopkins Multidisciplinary Cancer Committee

    Member

  • American Society for Clinical Oncology

    Member

  • Society for Melanoma Research

    Member

  • Society for Immunotherapy of Cancer

    Member

  • Eastern Cooperative Oncology Group

    Member

Videos & Media

Recent News Articles and Media Coverage

New Cancer treatments have perplexing side effects, The Washington Post , Jan 2, 2018

How Does Immunotherapy Work?, Melanoma Research Alliance, Feb. 2, 2016

In The Beginning, Hopkins Medicine, Fall 2014

Keytruda Just One of a New Class of Cancer Drugs to Restart the Immune System, Healthline News, Sept. 10, 2014

New Skin Cancer Drug Approved, CNN, Jan. 31, 2012

'Seize the Days' Project Documents a Life with Cancer, WAMU 88.5, Jan. 6, 2012

Giving Patients a Way to Share Their Stories, Cancer.Net, April 4, 2011

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile